Claus Meyer

Head of DCAL, PhD

Goethe University Frankfurt

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Claus Meyer, PhD, is the Head of the DCAL at Goethe University Frankfurt, Germany. His research focuses on the genetic and clinical aspects of acute leukemias, particularly involving KMT2A rearrangements and their implications for treatment and prognosis. Recent articles highlight the role of epigenetic regulators and immune checkpoints in leukemia, as well as novel diagnostic and therapeutic strategies for affected patients.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Jan Zuna

Charles University

CZECH REPUBLIC

View details

Lisa Russell

Senior Lecturer in Childhood Cancer and Haematology

Newcastle University

UNITED KINGDOM

View details

Andrea Biondi

Full Professor

University of Milano-Bicocca

ITALY

View details

Oscar Molina

SPAIN

View details

Sophie Kellaway

Assistant Professor

University of Nottingham

UNITED KINGDOM

View details

Senior Lecturer

Northumbria University

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Claus Meyer

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia.

Novel Diagnostic and Therapeutic Options for <i>KMT2A</i>-Rearranged Acute Leukemias.

KMT2A-MLLT1 and the Novel SEC16A-KMT2A in a Cryptic 3-Way Translocation t(9;11;19) Present in an Infant With Acute Lymphoblastic Leukemia.

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints

Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.

KMT2A-ARHGEF12, a therapy related fusion with poor prognosis

Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

Therapy-related acute myeloid leukemia with KMT2A-SNX9 gene fusion associated with a hyperdiploid karyotype after hemophagocytic lymphohistiocytosis

Collaborators (11)

Jan Zuna

Lisa Russell

Andrea Biondi

Oscar Molina

Sophie Kellaway

Simon Bomken

Giovanni Cazzaniga

Peter Keane

James Allan

Venetia Bigley

Deepali Pal

Make your next move.